Wells Fargo analyst Mohit Bansal maintained a Buy rating on Eli Lilly & Co on July 10 and set a price target of $1,280.00. The company’s shares closed last Friday at $1,188.58.TipRanks Welcomes a New ETF – NYSE:RANK TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Bansal covers the Healthcare sector, focusing on stocks such as Merck & Company, Gilead Sciences, and Eli Lilly & Co. According to TipRanks, Bansal has an average return of 11.1% and a 59.64% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Eli Lilly & Co with a $1,325.05 average price target, which is an 11.48% upside from current levels. In a report released on July 10, Bank of America Securities also assigned a Buy rating to the stock with a $1,334.00 price target.
Based on Eli Lilly & Co’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $19.8 billion and a net profit of $7.4 billion. In comparison, last year the company earned a revenue of $12.73 billion and had a net profit of $2.76 billion
